Finance

Beta
Lists
HIMS:NYSE
Hims & Hers Health Inc
$33.94
+0.21%
(+0.070) 1D
$34.65
+2.09% (+0.71)
Pre-market
Closed: Jun 26, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HIMS...
Mkt. cap
7.86B
Avg. vol.
19.47M
Volume
248.63K
52-wk high
$70.43
52-wk low
$13.74
EPS
-$0.09
Beta
2.37
Shares outstanding
223.08M
No. of employees
2K
Mkt. cap
7.86B
Avg. vol.
19.47M
Volume
248.63K
52-wk high
$70.43
52-wk low
$13.74
EPS
-$0.09
Beta
2.37
Shares outstanding
223.08M
No. of employees
2K
News stories
From sources across the web
Profile
Hims & Hers Health, Inc. is an American telehealth company established in 2017. The company provides prescription medications, over-the-counter medications, and personal care products. Hims & Hers operates with a direct-to-consumer model. Consumers consult licensed healthcare professionals and access treatments and products through the company's platform. Customers pay for a consultation with a doctor to prescribe the drug along with the price of the drug itself. The company has expanded its offerings to include health solutions for both men and women, along with mental health services. Wikipedia
About Hims & Hers Health Inc
CEO-
Employees2.44K
FoundedNov 2017
HeadquartersSan Francisco, California, United States
SectorHealth care provider
Websitehims.com
Analyst ratings
Based on 13 analysts giving stock ratings to HIMS in the past 3 months
Buy
Buy
4
Hold
9
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for HIMS in the last 3 months.
Highest
Current $33.94
$39.00 (+14.91%)
Average
$28.32 (-16.56%)
Lowest
$21.00 (-38.13%)
Analyst
Recommendation
Action
Price target
Projected
Date
Glen Santangelo
Barclays
Buy
Maintained
$39.00
+14.9%
06/18/2026
Jailendra Singh
Truist Financial
Hold
Reiterated
-
-
06/09/2026
Maria Ripps
Canaccord Genuity
Buy
Maintained
$32.00
-5.7%
06/02/2026
Allen Lutz
Bank of America Securities
Hold
Maintained
$25.00
-26.3%
05/28/2026
Brian Tanquilut
Jefferies
Hold
Maintained
$24.50
-27.8%
05/12/2026
Mark Mahaney
Evercore ISI
Hold
Maintained
$24.00
-29.3%
05/12/2026
Oliver Chen
TD Cowen
Hold
Reiterated
$25.00
-26.3%
05/12/2026
Craig Hettenbach
Morgan Stanley
Hold
Reiterated
$21.00
-38.1%
05/12/2026
Ryan MacDonald
Needham
Buy
Reiterated
$35.00
+3.1%
05/12/2026
Cory Carpenter
J.P. Morgan
Buy
Maintained
$33.00
-2.8%
05/12/2026
Daniel Grosslight
Citi
Hold
Reiterated
$28.00
-17.5%
05/12/2026
George Hill
Deutsche Bank
Hold
Reiterated
$25.00
-26.3%
05/05/2026
Michael Cherny
Leerink Partners
Hold
Maintained
-
-
04/16/2026
Jonna Kim
TD Cowen
Hold
Maintained
$23.00
-32.2%
03/27/2026
Unknown Analyst
Nephron
Buy
Upgraded
$35.00
+3.1%
03/09/2026
David Larsen
BTIG
Hold
Maintained
-
-
03/05/2026
Justin Patterson
KeyBanc
Hold
Maintained
-
-
02/24/2026
Last report
May 11, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.19 / $0.13
-244.04%miss
Revenue / Est. (USD)
608.10M / 616.85M
-1.42%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
544.83M
598.98M
617.82M
608.10M
Cost of goods sold
128.64M
156.92M
173.38M
182.82M
Cost of revenue
128.64M
156.92M
173.38M
182.82M
Research and development expenses
37.85M
40.58M
40.96M
46.94M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
351.62M
389.67M
386.64M
426.37M
Operating expense
389.47M
430.25M
427.60M
473.31M
Total operating expenses
518.11M
587.17M
600.99M
656.13M
Operating income
26.72M
11.81M
16.83M
-48.02M
Other non operating income
13.00K
-5.99M
-575.00K
-17.08M
EBT including unusual items
32.85M
12.22M
18.35M
-101.55M
EBT excluding unusual items
32.85M
12.22M
21.56M
-61.57M
Income tax expense
-9.65M
-3.55M
-2.25M
-9.44M
Effective tax rate
-29.38%
-29.05%
-12.25%
9.29%
Other operating expenses
-
-
-
-
Net income
42.50M
15.77M
20.60M
-92.12M
Net profit margin
7.80%
2.63%
3.33%
-15.15%
Earnings per share
0.29
0.28
0.22
-0.19
Interest and investment income
7.20M
8.01M
6.80M
5.03M
Interest expense
-1.08M
-1.60M
-1.50M
-1.50M
Net interest expenses
6.12M
6.41M
5.30M
3.53M
Depreciation and amortization charges
-
-
-
-
EBITDA
37.19M
29.48M
34.92M
-26.07M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of HIMS
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer